These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1162 related articles for article (PubMed ID: 2306754)

  • 1. Mouse tumors are heterogeneous in their susceptibility to syngeneic lymphokine-activated killer cells and delineate functional subsets in such effectors.
    Sensi M; Grazioli L; Rodolfo M; Parmiani G
    Cancer Immunol Immunother; 1990; 31(1):37-43. PubMed ID: 2306754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
    LeFor AT; Eisenthal A; Rosenberg SA
    J Immunol; 1988 Jun; 140(11):4062-9. PubMed ID: 3259603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T; Belfrage H; Bhiladvala P; Hedlund G
    J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance of different tumor cells to lysis by lymphokine activated killer cells can be mediated by distinct mechanisms.
    Bean P; Mazumder A
    Immunobiology; 1992 Jun; 185(1):63-77. PubMed ID: 1398742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of lymphokine-activated killer (LAK) cells from tumor-infiltrating lymphocytes.
    Nishimura T; Yagi H; Uchiyama Y; Hashimoto Y
    Cell Immunol; 1986 Jun; 100(1):149-57. PubMed ID: 2874890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic and functional heterogeneity of thymic and splenic lymphokine activated killer cells relative to ornithine sensitivity.
    Mehrotra P; Bear HD; Susskind BM
    Cell Immunol; 1991 Feb; 132(2):451-65. PubMed ID: 1899052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target cell membrane modification and susceptibility to lymphokine activated killer cell mediated lysis. I. Trinitrophenyl has no effect on murine normal cells and tumors.
    Lefor AT
    J Surg Res; 1991 Oct; 51(4):316-23. PubMed ID: 1921371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphokine-activated killer cells and aging in mice: significance for defining the precursor cell.
    Kawakami K; Bloom ET
    Mech Ageing Dev; 1987 Dec; 41(3):229-40. PubMed ID: 2892985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine trophoblast can be killed by lymphokine-activated killer cells.
    Drake BL; Head JR
    J Immunol; 1989 Jul; 143(1):9-14. PubMed ID: 2499634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.
    Rosenstein M; Yron I; Kaufmann Y; Rosenberg SA
    Cancer Res; 1984 May; 44(5):1946-53. PubMed ID: 6608989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphokine-activated killer (LAK) cells. IV. Characterization of murine LAK effector subpopulations.
    Ballas ZK; Rasmussen W
    J Immunol; 1990 Jan; 144(1):386-95. PubMed ID: 2104892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ; Krosnick JA; Rosenberg SA
    J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer (NK) cell subsets in the mouse. NK-1.1+/LGL-1+ cells restricted to lysing NK targets, whereas NK-1.1+/LGL-1- cells generate lymphokine-activated killer cells.
    Mason LH; Mathieson BJ; Ortaldo JR
    J Immunol; 1990 Jul; 145(2):751-9. PubMed ID: 2365999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity of the lymphokine-activated killer cell phenotype.
    Chadwick BS; Miller RG
    Cell Immunol; 1991 Jan; 132(1):168-76. PubMed ID: 1829653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphokine-activated killer cells in mouse bone marrow chimaeras. The relationship to natural killer cells and to alloreactive cytotoxic T cells.
    Sihvola M
    Scand J Immunol; 1985 Nov; 22(5):479-88. PubMed ID: 2867599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gelatin sponge model of effector recruitment: tumoricidal activity of adherent and non-adherent lymphokine-activated killer cells after culture in interleukin-2.
    Akporiaye ET; Barbieri CA; Stewart CC; Bender JG
    J Leukoc Biol; 1991 Feb; 49(2):189-96. PubMed ID: 1991999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precursor phenotype of lymphokine-activated killer cells in the mouse.
    Salup RR; Mathieson BJ; Wiltrout RH
    J Immunol; 1987 Jun; 138(11):3635-9. PubMed ID: 3108370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The specificity of lymphokine-activated killer (LAK) cells in vitro: fresh normal murine tissues are resistant to LAK-mediated lysis.
    Lefor AT; Rosenberg SA
    J Surg Res; 1991 Jan; 50(1):15-23. PubMed ID: 1987427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
    Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
    J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.